Orexo signs multi-year agreement with OptumRx and UnitedHealth Group
Published on March 12, 2014 at 5:20 AM
Orexo AB (STO:ORX), the manufacturer of ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), announced a multi-year agreement with UnitedHealth Group® and OptumRx® providing preferred coverage and reimbursement of ZUBSOLV®.
Under the agreement, ZUBSOLV will be given preferred, Tier 2 brand status on UnitedHealth Group commercial employer and individual formularies managed by OptumRx for the maintenance treatment of opioid dependence through June 30, 2014. Beginning on July 1, 2014 ZUBSOLV will become the only buprenorphine/naloxone combination product on all of UnitedHealth's closed and highly managed health plan formularies, inclusive of all brand and generic formulations.
"Orexo's mission is to increase access to medication-assisted treatment plans, help reduce relapse rates and improve successful patient outcomes - all critically important in the face of the growing opioid dependence epidemic in the US," said Robert DeLuca, R.Ph., President, Orexo U.S., Inc. "Our long term strategic partnership with UnitedHealth Group and OptumRx enables us to assist a greater number of patients who are incorporating a treatment option such as ZUBSOLV into their recovery plans."
"Orexo is dedicated to broadening the market access position for ZUBSOLV and this agreement with UnitedHealth Group and OptumRx is an important step in that direction. It is a major achievement and endorsement as health insurers with a firm control over their formularies recognize ZUBSOLV as the preferred buprenorphine/naloxone formulary product for the maintenance treatment of opioid dependence" said Nikolaj Sorensen, CEO and President of Orexo.
ZUBSOLV is an advanced sublingual tablet formulation for maintenance treatment of opioid dependence with high bioavailability, a fast dissolve time, small tablet size, and menthol flavor. The advanced formulation provided by ZUBSOLV was specifically designed to meet the needs expressed by patients. Meeting patient needs may have the potential to improve patient adherence, thus reducing relapse rates and improving successful patient outcomes. It is the only opioid dependence treatment option available in the highest level of child resistant, unit dose, F1 packaging, designed to reduce the chance of unintended pediatric exposure.